TRIAL TO ASSESS CHELATION THERAPY (TACT)

评估螯合疗法的试验 (TACT)

基本信息

批准号：
7375819
负责人：
PAMELA OUYANG
金额：
$ 5.22万
依托单位：
JOHNS HOPKINS UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2005
资助国家：
美国
起止时间：
2005-12-01 至 2006-11-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/7375819
关键词：
TRIAL ASSESS CHELATION THERAPY TACT

项目摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Coronary heart disease (CHD) is the leading cause of premature morbidity and mortality in the U.S. Currently proven treatments for CHD include lifestyle modification, drugs, and procedures. Despite the availability of these treatments, many patients seek out and receive alternative therapies, including the complementary and alternative medicine (CAM) practice called chelation therapy. Chelation therapy involve IV administration of disodium ethylenediaminetetraacetic acid (EDTA), combined with high dose antioxidant vitamin and mineral supplements. Thus, clinical benefit from chelation therapy, if seen, could be due to EDTA, antioxidants, mineral supplements, or a combination of these. The purpose of this large scale 5-year multi-center trial is: 1) to determine whether chelation or high dose supplements in patients with CHD reduces the incidence of clinical cardiovascular events; 2) to determine whether chelation and high-dose supplements have acceptable safety profiles; 3) To determine whether chelation or high-dose supplements improve the quality of life; 4) To conduct an economic analysis of chelation therapy and high dose supplements.

该子项目是利用 NIH/NCRR 资助的中心拨款提供的资源的众多研究子项目之一。子项目和研究者 (PI) 可能已从另一个 NIH 来源获得主要资金，因此可以在其他 CRISP 条目中得到体现。列出的机构是中心的机构，不一定是研究者的机构。冠心病 (CHD) 是美国过早发病和死亡的主要原因。目前经过验证的 CHD 治疗方法包括改变生活方式、药物和手术。尽管有这些治疗方法，许多患者仍在寻求并接受替代疗法，包括称为螯合疗法的补充和替代医学 (CAM) 实践。螯合疗法包括静脉注射乙二胺四乙酸二钠 (EDTA)，并结合高剂量的抗氧化维生素和矿物质补充剂。因此，如果发现螯合疗法的临床益处，则可能是由于 EDTA、抗氧化剂、矿物质补充剂或这些药物的组合。这项为期5年的大规模多中心试验的目的是：1）确定CHD患者服用螯合剂或高剂量补充剂是否可以降低临床心血管事件的发生率； 2) 确定螯合剂和高剂量补充剂是否具有可接受的安全性； 3) 确定螯合剂或大剂量补充剂是否可以改善生活质量； 4) 对螯合疗法和大剂量补充剂进行经济分析。